[BigDataNews | Reporter Lee Byunghak]
REV-MED (CEO Edward BG Shin) participated in the Arab Health 2025, the largest international medical device exhibition in the Middle East, held in Dubai, UAE from January 27 to 30.
During the exhibition, REV-MED introduced its proprietary self-derived biological substance extraction technologies, strengthening its presence in the Middle East and accelerating its entry into the global market for advanced regenerative medicine.
REV-MED showcased its TriCell and NovaStem platforms, which enable the efficient separation and concentration of immune cells and stem cells from the patient's own blood. Under the theme of Hybrid Aesthetics, the company also exhibited its Rewave microwave lifting device and the Brifill series of HA fillers, further diversifying its product portfolio.
REV-MED has acquired certifications from Japan's PMDA and China's NMPA for its self-derived blood separation and concentration devices.
A company representative stated,
“We are positioning ourselves as a global leader in the field of self-derived biological substance extraction and will continue to pioneer new frontiers in regenerative medicine through ongoing research and development.”
Following Arab Health 2025, REV-MED plans to expand cooperation with countries across the Middle East and accelerate its global market expansion.
Lee Byunghak, BigDataNews Reporter
Email: lbh@thebigdata.co.kr
Source: BigDataNews Original Article
[BigDataNews | Reporter Lee Byunghak]
REV-MED (CEO Edward BG Shin) participated in the Arab Health 2025, the largest international medical device exhibition in the Middle East, held in Dubai, UAE from January 27 to 30.
During the exhibition, REV-MED introduced its proprietary self-derived biological substance extraction technologies, strengthening its presence in the Middle East and accelerating its entry into the global market for advanced regenerative medicine.
REV-MED showcased its TriCell and NovaStem platforms, which enable the efficient separation and concentration of immune cells and stem cells from the patient's own blood. Under the theme of Hybrid Aesthetics, the company also exhibited its Rewave microwave lifting device and the Brifill series of HA fillers, further diversifying its product portfolio.
REV-MED has acquired certifications from Japan's PMDA and China's NMPA for its self-derived blood separation and concentration devices.
A company representative stated,
“We are positioning ourselves as a global leader in the field of self-derived biological substance extraction and will continue to pioneer new frontiers in regenerative medicine through ongoing research and development.”
Following Arab Health 2025, REV-MED plans to expand cooperation with countries across the Middle East and accelerate its global market expansion.
Lee Byunghak, BigDataNews Reporter
Email: lbh@thebigdata.co.kr
Source: BigDataNews Original Article